SCHEMBL7200489

SCHEMBL7200489

O=C(NO)C1(O)CNCCC1S(=O)(=O)N1CCC(c2cccc(F)c2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.44
SCD5 Q86SK9 2/20 0.39
DRD4 P21917 1/20 0.39
NPC1 O15118 1/20 0.39
KCNQ2 O43526 1/20 0.38
ADAMTS5 Q9UNA0 2/20 0.38
PARP10 Q53GL7 1/20 0.37
PKM P14618 1/20 0.37
TSHR P16473 1/20 0.37
CCR2 P41597 1/20 0.37
KCNH2 Q12809 1/20 0.37
MMP2 P08253 3/20 0.37
ADAM10 O14672 2/20 0.37
MMP9 P14780 1/20 0.37
MMP13 P45452 1/20 0.36
HDAC4 P56524 1/20 0.36
KMT2A Q03164 1/20 0.36
NAMPT P43490 1/20 0.36
AKT1 P31749 1/20 0.36
CHRM4 P08173 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7202601 0.88 MMP2 (0.49) USP5DRD4ADAMTS5MMP2ADAM10
SCHEMBL7199659 0.88 HSD11B1 (0.39) USP5DRD4ADAMTS5MMP2ADAM10
SCHEMBL7204534 0.88 USP5 (0.41) USP5NPC1ADAMTS5CCR2MMP2
SCHEMBL7201610 0.88 MMP2 (0.47) USP5MMP2ADAM10MMP9MMP13
SCHEMBL7204170 0.86 HTR2C (0.48) USP5PKMCCR2KCNH2MMP2
SCHEMBL7202653 0.84 MLNR (0.45) KCNH2MMP2MMP13KMT2A
SCHEMBL7204138 0.83 MMP13 (0.48) USP5SCD5MMP2MMP9MMP13
SCHEMBL7204092 0.82 HDAC4 (0.40) SCD5TSHRCCR2KCNH2MMP2
SCHEMBL7201770 0.82 MMP2 (0.44) DRD4TSHRKCNH2MMP2ADAM10
SCHEMBL7205659 0.82 TP53 (0.41) MMP2ADAM10MMP9MMP13NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 USP5 1778/4885SCD5 2348/4885DRD4 4234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.